NTLA
Price
$25.06
Change
+$1.16 (+4.85%)
Updated
Oct 15, 11:16 AM (EDT)
Capitalization
2.57B
21 days until earnings call
Intraday Buy/Sell Signals
OCGN
Price
$1.71
Change
+$0.08 (+4.91%)
Updated
Oct 15, 11:16 AM (EDT)
Capitalization
509.06M
22 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

NTLA vs OCGN

Header iconNTLA vs OCGN Comparison
Open Charts NTLA vs OCGNBanner chart's image
Intellia Therapeutics
Price$25.06
Change+$1.16 (+4.85%)
Volume$6.1K
Capitalization2.57B
Ocugen
Price$1.71
Change+$0.08 (+4.91%)
Volume$15.73K
Capitalization509.06M
NTLA vs OCGN Comparison Chart in %
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. OCGN commentary
Oct 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and OCGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 16, 2025
Stock price -- (NTLA: $23.90 vs. OCGN: $1.63)
Brand notoriety: NTLA and OCGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 82% vs. OCGN: 136%
Market capitalization -- NTLA: $2.57B vs. OCGN: $509.06M
NTLA [@Biotechnology] is valued at $2.57B. OCGN’s [@Biotechnology] market capitalization is $509.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 0 FA rating(s) are green whileOCGN’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 0 green, 5 red.
  • OCGN’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than OCGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 5 TA indicator(s) are bullish while OCGN’s TA Score has 4 bullish TA indicator(s).

  • NTLA’s TA Score: 5 bullish, 4 bearish.
  • OCGN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than OCGN.

Price Growth

NTLA (@Biotechnology) experienced а +16.90% price change this week, while OCGN (@Biotechnology) price change was -7.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.44%. For the same industry, the average monthly price growth was +17.42%, and the average quarterly price growth was +81.94%.

Reported Earning Dates

NTLA is expected to report earnings on Nov 06, 2025.

OCGN is expected to report earnings on Nov 07, 2025.

Industries' Descriptions

@Biotechnology (+0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($2.57B) has a higher market cap than OCGN($509M). NTLA (104.931) and OCGN (102.484) have similar YTD gains . OCGN has higher annual earnings (EBITDA): -52.34M vs. NTLA (-501.87M). NTLA has more cash in the bank: 460M vs. OCGN (27M). OCGN has less debt than NTLA: OCGN (32.8M) vs NTLA (103M). NTLA has higher revenues than OCGN: NTLA (52.9M) vs OCGN (4.75M).
NTLAOCGNNTLA / OCGN
Capitalization2.57B509M504%
EBITDA-501.87M-52.34M959%
Gain YTD104.931102.484102%
P/E RatioN/AN/A-
Revenue52.9M4.75M1,113%
Total Cash460M27M1,704%
Total Debt103M32.8M314%
FUNDAMENTALS RATINGS
NTLA vs OCGN: Fundamental Ratings
NTLA
OCGN
OUTLOOK RATING
1..100
1677
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
9890
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3536
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (37) in the Biotechnology industry is somewhat better than the same rating for OCGN (92) in the null industry. This means that NTLA’s stock grew somewhat faster than OCGN’s over the last 12 months.

OCGN's Profit vs Risk Rating (90) in the null industry is in the same range as NTLA (98) in the Biotechnology industry. This means that OCGN’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's SMR Rating (98) in the Biotechnology industry is in the same range as OCGN (100) in the null industry. This means that NTLA’s stock grew similarly to OCGN’s over the last 12 months.

NTLA's Price Growth Rating (35) in the Biotechnology industry is in the same range as OCGN (36) in the null industry. This means that NTLA’s stock grew similarly to OCGN’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as OCGN (100) in the null industry. This means that NTLA’s stock grew similarly to OCGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAOCGN
RSI
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
84%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 7 days ago
81%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 8 days ago
78%
Bullish Trend 8 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AFPPX10.080.02
+0.20%
American Funds® Core Plus Bond R4
JNEMX22.88N/A
N/A
JPMorgan International Equity R6
TOECX41.49N/A
N/A
Touchstone Mid Cap Growth C
PPYPX9.11N/A
N/A
PIMCO RAE International I-2
FWOEX18.31N/A
N/A
Fidelity Advisor Women's Leadership M

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+0.57%
VCYT - NTLA
69%
Closely correlated
-0.41%
BEAM - NTLA
63%
Loosely correlated
+0.12%
CRSP - NTLA
63%
Loosely correlated
+1.60%
RXRX - NTLA
56%
Loosely correlated
+6.51%
AXON - NTLA
55%
Loosely correlated
-0.75%
More

OCGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCGN has been loosely correlated with RAIN. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if OCGN jumps, then RAIN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCGN
1D Price
Change %
OCGN100%
+1.87%
RAIN - OCGN
53%
Loosely correlated
-1.04%
ARRY - OCGN
47%
Loosely correlated
+3.19%
AXON - OCGN
46%
Loosely correlated
-0.75%
IPSC - OCGN
45%
Loosely correlated
+1.84%
NTLA - OCGN
42%
Loosely correlated
+0.57%
More